Table 3.
Frequency of Blood Pressure Recordings Before and During Mirabegron Treatment
| Netherlands | Spain | UK | Finland | |||||
|---|---|---|---|---|---|---|---|---|
| Pre-DHPC | Post-DHPC | Pre-DHPC | Post-DHPC | Pre-DHPC | Post-DHPC | Pre-DHPC | Post-DHPC | |
| All mirabegron initiations | N = 4,418 | N = 3,124 | N = 12,584 | N = 7,124 | N = 9,951 | N = 7,497 | N = 3,412 | N = 3968 |
| n (%) with BP record before initiation | 1,747 (40) | 1,228 (39) | 7,135 (57) | 3,909 (55) | 5,720 (57) | 4,505 (60) | 1,133 (33) | 1,331 (34) |
| Duration (months) of total mirabegron treatmenta, median (IQR) | 5 (1–17) | 2 (1–6) | 8 (2–21) | 3 (1–8) | 10 (2–23) | 4 (1–9) | 8 (1–20) | 3 (1–7) |
| Number of BP records per person-quarter year of treatment, median (IQR) | 0.0 (0.0–0.4) | 0.0 (0.0–0.4) | 0.0 (0.0–0.9) | 0.0 (0.0–0.9) | 0.0 (0.0–0.6) | 0.0 (0.0–0.7) | 0.0(0.0–0.2) | 0.0 (0.0–0.2) |
| Documented hypertension at mirabegron initiationb | N = 1,272 | N = 862 | N = 5,097 | N = 2,762 | N = 3,769 | N = 2,968 | N = 819 | N = 996 |
| Duration (months) of total mirabegron treatmenta, median (IQR) | 6 (1–18) | 2 (1–6) | 10 (3–22) | 3 (1–8) | 11 (3–23) | 4 (1–8) | 9 (3–19) | 4 (1–8) |
| Number of BP records/per person-quarter year of treatment, median (IQR) | 0.4 (0.0–1.1) | 0.3 (0.0–1.3) | 0.5 (0.0–1.2) | 0.4 (0.0–1.2) | 0.4 (0.0–0.9) | 0.4 (0.0–1.1) | 0.0 (0.0–2.3) | 0.0 (0.0–2.4) |
Notes: aMirabegron treatment including gaps < 12 months. bExcluding hypertension with unconfirmed blood pressure; Pre-DHPC person time was censored at DHPC dissemination date.
Abbreviations: BP, blood pressure; IQR, interquartile range.